Modern possibilities of topical therapy for foot mycosis

Cover Page

Cite item

Full Text

Abstract

Foot mycosis is one of the most common skin diseases. Its prevalence in the general population ranges from 5 to 20%. The main causative agents of foot mycosis are dermatophytes; they account for 80-90% of cases. Terbinafine is an antifungal drug that belongs to the allylamine group, with a wide spectrum of antifungal activity. It has been registered since 1991 in Europe and is included in the WHO Model List of Essential Medicines. The article discusses the features of the use of various forms of terbinafine, depending on the clinical picture of foot mycosis. It presents Russian and foreign data on the efficacy and safety of terbinafine in the topical therapy of foot mycosis.

About the authors

Ivan S. Maximov

Sechenov First Moscow State Medical University (Sechenov University)

Email: maximov.is@mail.ru
ассистент каф. кожных и венерических болезней ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Moscow, Russia

References

  1. Woodfolk JA. Allergy and dermatophytes. Clin Microbiol Rev 2005; 18 (1): 30-43. doi: 10.1128/CMR.18.1.30-43.2005
  2. Al Hasan M, Fitzgerald SM, Saoudian M, Krishnaswamy G. Dermatology for the practicing allergist: Tinea pedis and its complications. Clin Mol Allergy 2004; 2 (1): 5. doi: 10.1186/1476-7961-2-5
  3. Соколова ТВ, Малярчук ТА. Эпидемиология микозов стоп (Обзор литературы). Эпидемиология и вакцинопрофилактика. 2015; 13 (1): 70-4.
  4. Hay RJ, Campbell CK, Wingfield R, Clayton YM. A comparative study of dermatophytosis in coal miners and dermatological outpatients. Br J Ind Med 1983; 40 (3): 353-5. doi: 10.1136/oem.40.3.353
  5. Noguchi H, Hiruma M, Kawada A et al. Tinea pedis in members of the Japanese Self-defence Forces: relationships of its prevalence and its severity with length of military service and width of interdigital spaces. Mycoses 38 (11-12): 494-9. http://www.ncbi.nlm.nih.gov/pubmed/8720203
  6. Lacroix C, Baspeyras M, de La Salmoniere P et al. Tinea pedis in European marathon runners. J Eur Acad Dermatol Venereol 2002; 16 (2): 139-42. doi: 10.1046/j.1468-3083.2002.00400.x
  7. Djeridane A, Djeridane Y, Ammar-Khodja A. Epidemiological and aetiological study on tinea pedis and onychomycosis in Algeria. Mycoses 2006; 49 (3): 190-6. doi: 10.1111/j.1439-0507.2006.01230.x
  8. Dhib I, Fathallah A, Yaacoub A et al. Clinical and mycological features of onychomycosis in central Tunisia: a 22 years retrospective study (1986-2007). Mycoses 2013; 56 (3): 273-80. doi: 10.1111/myc.12016
  9. Drakensjo IT, Chryssanthou E. Epidemiology of dermatophyte infections in Stockholm, Sweden: a retrospective study from 2005-2009. Med Mycol 2011; 49 (5): 484-8. doi: 10.3109/13693786.2010.540045
  10. Alvarez MI, Gonzalez LA, Castro LA. Onychomycosis in Cali, Colombia. Mycopathologia 2004;(2): 181-6. doi: 10.1023/B: MYCO.0000041866.85314.e4
  11. Рукавишникова ВМ. Микозы стоп. М.: Эликс Ком, 2003.
  12. Яковлев А.Б. Эффективность и безопасность тербинафина при комбинированной терапии разных клинических форм микоза стоп. Эффективная фармакотерапия. 2018; 21: 4-9.
  13. Favre B, Ryder NS. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother 1996; 40 (2): 443-7. doi: 10.1128/aac.40.2.443
  14. Sugiura M, Hata Y, Fukuda T et al. One-week application of terbinafine cream compared with four-week application in treatment of Tinea pedis. Nihon Ishinkin Gakkai Zasshi 2001; 42 (4): 223-8. doi: 10.3314/jjmm.42.223
  15. Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in shortterm treatment of tinea pedis. Int J Dermatol 1996; 35 (8): 591-3. doi: 10.1111/j.1365-4362.1996.tb03668.x
  16. Хамаганова И.В., Цыкин А.А. Раствор тербинафина 1% пленкообразующий в терапии у пациентов, длительно страдающих микозами стоп. Мед. совет. 2019; 12: 132-5.
  17. Li RY, Wang AP, Xu JH et al. Efficacy and safety of 1% terbinafine film-forming solution in Chinese patients with tinea pedis: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Clin Drug Investig 2014; 34 (3): 223-30. doi: 10.1007/s40261-014-0171-8
  18. Ortonne J, Korting H, Viguie-Vallanet C et al. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete’s foot): a randomized, double-blind, placebo-controlled study. J Eur Acad Dermatology Venereol 2006; 20 (10): 1307-13. doi: 10.1111/j.1468-3083.2006.01807.x
  19. Evans EGV, Bodman B, Williamson DM et al. Comparison of terbinafine and clotrimazole in treating tinea pedis. Br Med J 1993; 307 (6905): 645-7. doi: 10.1136/bmj.307.6905.645

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies